LPKF Laser & Electronics Reports Second Quarter 2025 Earnings
LPKF Laser & Electronics (ETR:LPK) Second Quarter 2025 Results
Key Financial Results
- Revenue: €36.5m (up 16% from 2Q 2024).
- Net income: €1.35m (up from €1.84m loss in 2Q 2024).
- Profit margin: 3.7% (up from net loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
LPKF Laser & Electronics Earnings Insights
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Electronic industry in Germany.
Performance of the German Electronic industry.
The company's shares are down 4.6% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on LPKF Laser & Electronics' balance sheet health.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:LPK
LPKF Laser & Electronics
Develops, manufactures, and sells laser-based solutions for the technology industry worldwide.
Exceptional growth potential with excellent balance sheet.
Similar Companies
Market Insights
Weekly Picks

OPTH: A licensed manufacturer already selling MDMA while peers still wait on trials

Why Amdocs is a high conviction Buy for me?
Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Recently Updated Narratives
High-Growth Emerging Commercial Stage Biotech

ALL ABOARD THE VALUE TRAIN: WHY $RAIL MIGHT BE HEADED NORTH - FREIGHTCAR AMERICA - Long term price target of $25

Capitalizing on rising semiconductor complexity
Popular Narratives


